Bayer IR Newsfeed: Events

08.05.08: Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration

ir@bayer-ag.de — Thu, 8 May 2008 08:35:04 +0200

Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration

International study to evaluate efficacy and safety in treating a leading cause of blindness

mehr ...

06.05.08: Bayer Schering Pharma to market new low-dose oral contraceptive YAZ� in Europe

ir@bayer-ag.de — Tue, 6 May 2008 08:35:04 +0200

Bayer Schering Pharma to market new low-dose oral contraceptive YAZ� in Europe

mehr ...

28.04.08: Bayer HealthCare and Regeneron Announce Encouraging 32-week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration

ir@bayer-ag.de — Mon, 28 Apr 2008 17:06:38 +0200

Bayer HealthCare and Regeneron Announce Encouraging 32-week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration

Gains in visual acuity achieved in initial 12-week fixed dosing phase of study maintained in PRN (as-needed) dosing phase

mehr ...

25.04.08: Werner Wenning at the Bayer AG Annual Stockholders' Meeting

ir@bayer-ag.de — Fri, 25 Apr 2008 10:00:05 +0200

"2007 was Bayer's most successful year to date"

Previous year's record levels and earnings targets exceeded / Dividend to be raised 35 percent to EUR 1.35 / Good start to fiscal 2008 / Bayer Climate Program being implemented and expanded

mehr ...

24.04.08: Interim report for the first quarter of 2008

ir@bayer-ag.de — Thu, 24 Apr 2008 07:35:04 +0200

Bayer off to an excellent start in 2008

Sales up 2.4 percent to EUR 8,536 million / EBITDA before special items up 9.8 percent to EUR 2,185 million / EBIT before special items up 8.9 percent to EUR 1,497 million / Full-year guidance for CropScience raised / Positive Group forecast confirmed

mehr ...

21.04.08: Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin�

ir@bayer-ag.de — Mon, 21 Apr 2008 18:05:04 +0200

Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin�

mehr ...

02.04.08: Bayer HealthCare Affiliate MEDRAD Announces Completion of Subsequent Offering Period for Shares of Possis Medical

ir@bayer-ag.de — Wed, 2 Apr 2008 14:35:04 +0200

Bayer HealthCare Affiliate MEDRAD Announces Completion of Subsequent Offering Period for Shares of Possis Medical

Merger to Be Completed Shortly

mehr ...

31.03.08: Bayer appeals invalidity ruling on its Yasmin� Patent

ir@bayer-ag.de — Mon, 31 Mar 2008 19:10:04 +0200

Bayer appeals invalidity ruling on its Yasmin� Patent

Appeal will be heard by the Federal Circuit

mehr ...

26.03.08: Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period

ir@bayer-ag.de — Wed, 26 Mar 2008 13:35:04 +0100

Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period

Subsequent Offering Period Expires on Tuesday, April 1, 2008

mehr ...

11.03.08: Bayer HealthCare to acquire OTC Business of Sagmel, Inc.

ir@bayer-ag.de — Tue, 11 Mar 2008 08:05:04 +0100

Bayer HealthCare to acquire OTC Business of Sagmel, Inc.

Acquisition strengthens Bayer Consumer Care's Presence in Eastern Europe

mehr ...

03.03.08: Court decides against Bayer's Yasmin� patent

ir@bayer-ag.de — Mon, 3 Mar 2008 22:25:09 +0100

Court decides against Bayer's Yasmin� patent

Bayer HealthCare margin target (EBITDA before special items) for 2008 slightly adjusted - margin target for 2009 remains unchanged / Company will consider its legal options

mehr ...

28.02.08: Spring Financial News Conference:

ir@bayer-ag.de — Thu, 28 Feb 2008 07:35:02 +0100

Wenning: 2007 was Bayer's most successful year to date

Sales grew 11.8 percent to EUR 32,385 million / EBITDA before special items advanced 21.4 percent to EUR 6,777 million / Performance target for 2007 exceeded: underlying EBITDA margin of 20.9 percent / EBIT before special items climbed 23.2 percent to EUR 4,287 million / Group net income totaled EUR 4,711 million - boosted by divestiture proceeds / Further earnings increase expected for 2008

mehr ...

26.02.08: Bayer proposes increased dividend for 2007 of EUR 1.35 per share

ir@bayer-ag.de — Tue, 26 Feb 2008 13:10:03 +0100

Bayer proposes increased dividend for 2007 of EUR 1.35 per share

mehr ...

20.02.08: Bayer will vigorously defend itself against Kogenate patent infringement suit filed by Novartis

ir@bayer-ag.de — Wed, 20 Feb 2008 16:40:03 +0100

Bayer will vigorously defend itself against Kogenate patent infringement suit filed by Novartis

mehr ...

18.02.08: Bayer and Onyx Provide Update on Phase III Trial of Nexavar� in Patients with Non-Small Cell Lung Cancer

ir@bayer-ag.de — Mon, 18 Feb 2008 16:05:02 +0100

Bayer and Onyx Provide Update on Phase III Trial of Nexavar� in Patients with Non-Small Cell Lung Cancer

mehr ...